Immunocompromised people and those who are age 65 or older should get a second dose of the 2024-2025 COVID-19 vaccine, according to the latest recommendations from the Centers for Disease Control ...

Vectura and Hikma have extended their partnership, signing an agreement to develop a generic of GlaxoSmithKline’s asthma drug, Serevent, for the US market. The product is codenamed VR730 ...

Hikma Pharmaceuticals PLC, which is headquartered in London, plans to acquire parts of Xellia Pharmaceuticals' finished dosage form business and assets, including a commercial portfolio and ...

Not for use in untreated open-angle glaucoma. Reevaluate periodically. Change dose gradually. Withdrawal symptoms on abrupt cessation or dose reduction. Suicidal ideation. Psychosis. Mania.

Hikma will acquire parts of Xellia's US finished dosage form business and assets. According to its statement this will ...

Low dose birth control pills may have fewer side effects compared with older, higher-dose ones, but certain groups may still have increased health risks. If they aren’t taken correctly ...

Hikma Pharmaceuticals (GB:HIK) has released an update. Hikma Pharmaceuticals has decided to reappoint PricewaterhouseCoopers LLP as its external auditor starting in 2026, following a competitive ...

Hikma Pharmaceuticals Usa Inc was founded in 2011 and operates in Eatontown, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100 ...

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.99% to £19.98 Friday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 0. ...

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Riad Mishlawi, Hikma’s CEO, said: “I am pleased ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...